Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Rebinyn to Treat Hemophilia B

Novo Nordisk news release; 2018 Feb 8

The FDA has approved Rebinyn for the treatment of hemophilia B.

Indications: Rebinyn, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA-derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes.
  • Perioperative management of bleeding.

Dosage and administration: 40 IU/kg body weight for minor and moderate bleeds/minor surgery, and 80 IU/kg body weight for major bleeds/major surgery.

Efficacy and safety: In phase 3 studies, a single dose of 40 IU/kg in adults elevated factor activity above baseline levels by 94% and sustained average factor levels of 17% 7 days post-dose. Adults also achieved an 83-hour average half-life after receiving a single infusion.

Side effects/risks: The most common adverse reactions are itching and injection site reactions.


Novo Nordisk launches Rebinyn in the United States for people with hemophilia B. [news release]. Plainsboro, NJ: Novo Nordisk Inc. February 8, 2018. Accessed February 12, 2018.

Rebinyn [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2018. Accessed February 12, 2018.

This Week's Must Reads

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005

Adding mobile apheresis to community blood drives, Anthony D et al. AABB 2018, Poster BBC 135

Study assesses blood delivery errors, Vossoughi S et al. AABB 2018, Abstract QT4

CAR T-cell cost effectiveness in ALL, Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530

Must Reads in Bleeding Disorders

Laced synthetic cannabinoid leads to bleeding, Kelkar AH et al. N Engl J Med. 2018;379:1216-23.

Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Watch for RBC adhesion in men with sickle cell , Annual meeting of the Foundation for Sickle Cell Disease Research

FDA approves Jivi for hemophilia A, Package insert, news release